Patent ID: 11890296
Assignee: FUJIFILM CORPORATION
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 4:
5. A method for enhancing an anti-tumor effect, including administering a dihydroorotate dehydrogenase inhibitor compound to a subject in combination with cytarabine,
wherein the tumor cells are cytarabine-resistant leukemia cells; and
the dihydroorotate dehydrogenase inhibitor compound is at least one or more compounds selected from the group consisting of Brequinar, Vidofludimus, Teriflunomide, Leflunomide, N-(2-chloro-6-fluorophenyl)-4-[4-ethyl-3-(hydroxymethyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-5-fluoro-2-{[(2S)-1,1,1-trifluoropropan-2-yl]oxy} benzamide, (S)-4-chlorophenyl 6-chloro-1-(4-hydroxyphenyl)-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-carboxylate, and a compound represented by General Formula (1), or a salt thereof,, in the formula,
G1 is a CH or nitrogen atom;
R1 is a hydrogen atom, a halogen atom, a C1-6 alkyl group which may be substituted, or a C3-8 cycloalkyl group which may be substituted; and
R2 is an aryl group which may be substituted or a bicyclic heterocyclic group which may be substituted, or
the dihydroorotate dehydrogenase inhibitor compound is at least one or more compounds selected from the group consisting of ASLAN003 (2-((3,5-difluoro-3′-methoxybiphenyl-4-yl)amino) nicotinic acid) and 5-cyclopropyl-2-((1-phenyl-1H-indol-5-yl)amino) nicotinic acid, or a salt thereof.